Literature DB >> 2968441

Ultrastructural observations on myelinated fibres in experimental diabetes: effect of the aldose reductase inhibitor ponalrestat given alone or in conjunction with insulin therapy.

S Bhoyrul1, A K Sharma, D Stribling, D D Mirrlees, R G Peterson, M O Farber, P K Thomas.   

Abstract

Six groups of rats were studied over a 12-week period: onset and end controls, untreated diabetics, ponalrestat-treated diabetics, insulin-treated diabetics, and diabetics treated with ponalrestat and insulin. The concentrations of glucose, sorbitol and fructose significantly increased and that of myo-inositol significantly decreased in the sciatic nerve of untreated diabetic animals. Ponalrestat administration completely normalized sorbitol levels and partially corrected fructose and myo-inositol concentrations without altering nerve glucose levels. The biochemical abnormalities were also corrected in both the insulin-treated and insulin and ponalrestat-treated diabetic animals. Myelinated fibre cross-sectional areas and axonal areas were significantly less in the tibial nerve of diabetic animals as compared with age-matched controls. Insulin treatment partially corrected the reduction in fibre and axonal area but teased fibre preparations showed an excess of axonal degeneration as compared with controls, untreated diabetics and ponalrestat-treated diabetics. Ponalrestat given alone or in conjunction with insulin therapy did not correct the reduction in fibre or axonal area and single isolated fibres from diabetic animals treated with ponalrestat and insulin showed a marked excess of axonal degeneration, probably related to hypoglycaemia. The study fails to reveal any significant beneficial effect of aldose reductase inhibition on the structural abnormalities in peripheral nerve in experimental diabetes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2968441     DOI: 10.1016/0022-510x(88)90151-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.

Authors:  A A Sima; A Prashar; W X Zhang; S Chakrabarti; D A Greene
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

2.  Number and ultrastructure of epithelial cells in crypts and villi along the streptozotocin-diabetic small intestine: a quantitative study on the effects of insulin and aldose reductase inhibition.

Authors:  S A Zoubi; M D Williams; T M Mayhew; R A Sparrow
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  Small intestinal morphology in experimental diabetic rats: a stereological study on the effects of an aldose reductase inhibitor (ponalrestat) given with or without conventional insulin therapy.

Authors:  T M Mayhew; F L Carson; A K Sharma
Journal:  Diabetologia       Date:  1989-09       Impact factor: 10.122

4.  Mechanisms of adaptation in rat small intestine: regional differences in quantitative morphology during normal growth and experimental hypertrophy.

Authors:  T M Mayhew; F L Carson
Journal:  J Anat       Date:  1989-06       Impact factor: 2.610

5.  Relative growth and maturation of axon size and myelin thickness in the tibial nerve of the rat. 2. Effect of streptozotocin-induced diabetes.

Authors:  P K Thomas; J P Fraher; D O'Leary; M A Moran; M Cole; R H King
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

6.  The small intestine in experimental diabetes: cellular adaptation in crypts and villi at different longitudinal sites.

Authors:  S A Zoubi; T M Mayhew; R A Sparrow
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Renal nerve ultrastructural alterations in short term and long term experimental diabetes.

Authors:  Karina Laurenti Sato; Luciana Sayuri Sanada; Renata da Silva Ferreira; Maria Carolina Del Bem de Barros Oliveti de Marco; Jaci Airton Castania; Helio Cesar Salgado; Randy Alan Nessler; Valeria Paula Sassoli Fazan
Journal:  BMC Neurosci       Date:  2014-01-05       Impact factor: 3.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.